Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022.
Pellacani G, Schlesinger T, Bhatia N, Berman B, Lebwohl M, Cohen JL, Patel GK, Kunstfeld R, Hadshiew I, Lear JT. Pellacani G, et al. Among authors: kunstfeld r. J Eur Acad Dermatol Venereol. 2024 Jan;38 Suppl 1:3-15. doi: 10.1111/jdv.19636. J Eur Acad Dermatol Venereol. 2024. PMID: 38116638 Clinical Trial.
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy.
Zila N, Eichhoff OM, Steiner I, Mohr T, Bileck A, Cheng PF, Leitner A, Gillet L, Sajic T, Goetze S, Friedrich B, Bortel P, Strobl J, Reitermaier R, Hogan SA, Martínez Gómez JM, Staeger R, Tuchmann F, Peters S, Stary G, Kuttke M, Elbe-Bürger A, Hoeller C, Kunstfeld R, Weninger W, Wollscheid B, Dummer R, French LE, Gerner C, Aebersold R, Levesque MP, Paulitschke V. Zila N, et al. Among authors: kunstfeld r. Clin Cancer Res. 2024 Jan 5;30(1):159-175. doi: 10.1158/1078-0432.CCR-23-0562. Clin Cancer Res. 2024. PMID: 37861398
Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study.
Schadendorf D, Hauschild A, Fosko S, Zloty D, Labeille B, Grob JJ, Puig S, Makrutzki M, Gilberg F, Hong A, Dréno B, Rogers G, Kunstfeld R. Schadendorf D, et al. Among authors: kunstfeld r. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e526-e529. doi: 10.1111/jdv.16446. Epub 2020 May 19. J Eur Acad Dermatol Venereol. 2020. PMID: 32277508 No abstract available.
Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, Stephan J, Mangana J, Kunstfeld R, Pehamberger H, Aebersold R, Dummer R, Levesque MP. Paulitschke V, et al. Among authors: kunstfeld r. EMBO J. 2019 Aug 1;38(15):e95874. doi: 10.15252/embj.201695874. Epub 2019 Jun 26. EMBO J. 2019. PMID: 31267558 Free PMC article.
Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.
Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A. Hansson J, et al. Among authors: kunstfeld r. Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448. Eur J Dermatol. 2018. PMID: 30698147 Clinical Trial.
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J. Basset-Séguin N, et al. Among authors: kunstfeld r. Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5. Eur J Cancer. 2017. PMID: 29073584 Free article. Clinical Trial.
56 results